Tiny Gem Archives - Page 39 of 44

ThursdayJul 21, 2022 11:15 am

Mullen Automotive Inc. (NASDAQ: MULN) Recently Featured on Benzinga, Noting Solid-State Battery Test Results that Exceed Expectations, Extend EV Range

MULN shares traded higher after Benzinga stated that the emerging EV manufacturer had reported higher-than-expected battery test resultsData shows the company’s proprietary solid-state polymer batteries can deliver more than 600 miles of range on a full chargeThe company plans to include the new batteries in its second-generation Mullen FIVE EV Crossover Mullen Automotive (NASDAQ: MULN) was featured in a recent Benzinga Brief. The short summary noted that the company, an emerging electric-vehicle manufacturer, had reported results of its solid-state polymer battery testing, which exceeded expectations (https://ibn.fm/XI6Fa). Noting that shares were trading higher after the news, Benzinga quoted David Michery, Mullen…

WednesdayJul 20, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pending Start of Human Nicotine Study, NIC-H22-1, Leveraging Fast-Growing Global Nicotine Pouches Market

Lexaria Bioscience Corp. expects the upcoming human nicotine study to produce evidence that its patented DehydraTECH(TM) technology can enhance oral-tissue absorption with reduced negative experiencesData collected from animal study NIC-A21-1 showed that DehydraTECH enhanced oral nicotine pouches delivered peak nicotine levels in the bloodstream of animals 10x to 20x faster than the controlThe global nicotine pouches market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, being one of the fastest growing segments in the nicotine industryLexaria's pipeline addresses serious unmet patient or consumer needs with greater market potential, addressing multiple mainstream applications…

TuesdayJul 19, 2022 9:45 am

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

Treating patients with primary or secondary bone cancer remains goal, says company CEORadiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cellsQSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients QSAM Biosciences (OTCQB: QSAM), a company developing a new class of drugs called radiopharmaceuticals, is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its proprietary radiopharmaceutical…

MondayJul 18, 2022 11:15 am

Cepton, Inc. (NASDAQ: CPTN) Furthers Tier 1 Collaboration, Aims to Make Lidar a Standard Feature in Transportation

CPTN produces near-range to ultra-long-range lidar sensors, perception solutions, and software for leading OEM manufacturers across the automotive and smart infrastructure marketsCepton aims to make lidar standard in every vehicle to enable safe assisted driving and autonomyCPTN's collaboration with Japan-based Koito Manufacturing Co. Ltd. led to ADAS lidar series production award from General MotorsCepton lidar sensors to be used in upcoming GM models featuring its Ultra Cruise advanced driver-assist system starting next year Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, aims to make its proprietary technology standard in all consumer vehicles to support…

MondayJul 18, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications

Researchers have run into the issue of solubility of molecules intended for absorption, ultimately affecting drug effectiveness and inhibiting patient recoveryThis has forced the exploration of new drug delivery technologies, with Lexaria’s patented DehydraTECH(TM) technology proving to be the most innovative, useful, and effectiveDehydraTECH(TM) technology has seen application in oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases, PDE5 inhibitors, and CBD for hypertensionThe recent expansion of the Cannadips Brand into Europe, Japan, and South Africa highlights the proliferation of DehydraTECH and a significant growth in its market share, particularly in the CBD spaceLexaria is excited…

ThursdayJul 14, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Licensee Expands Manufacturing Agreements to Include Europe, Japan, and South Africa

Lexaria's patented DehydraTECH(TM) enhancement technology targets key market segments including nicotine replacement, CBD, cardiovascular and antiviral drugs, human hormones, and PDE5 inhibitorsDehydraTECH-enabled drug and consumer products provide faster delivery times, increased bioavailability, increased brain absorption, improved drug potency, lower administration costs, and mask unwanted tastesThe global CBD market was valued at $5.18 billion in 2021 and is expected to grow at a CAGR of 16.8% from 2022 to 2030, resulting in a revenue forecast of $22.05 billion by 2030 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that Boldt Runners Corporation, licensee of its patented…

WednesdayJul 13, 2022 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Solidifies Its Detroit Presence with New Office in Troy; Poised to Be Integral Part of Latest Auto Trends

Cepton has opened a new dedicated automotive office in Metro Detroit - a clear sign of its growing relationship with General Motors and the American auto industryCompany solidifies itself as a key player in lidar; Metro Detroit office serves as automotive hub providing local support to OEM and Tier 1 partnersCepton boasts collaboration with Ford, expands its ongoing partnership with Koito Manufacturing, a leading tier-1 automotive lighting supplier, and remains engaged with the top 10 global automakers "I'm incredibly proud that our Silicon Valley company, Cepton, has earned Detroit's trust," said Dr. Jun Pei, Cepton (NASDAQ: CPTN) Co-Founder and CEO,…

TuesdayJul 12, 2022 12:00 pm

Emerging iGaming Technology Trends Fuel Golden Matrix Group Inc.’s (NASDAQ: GMGI) B2B Growth Strategy

Enhanced graphics, Gamification, AI-powered loyalty systems and data analytics redefining iGaming experience and generating higher player yields for online operators.GMGI sets industry standard, offers 10,000+ games across 25+ providersCompany provides highly configurable, modular, white-label, turnkey gaming platforms compatible with all major operating systems, browsers, devicesCompany recently reported 221% Q2-2022 growth, 15 consecutive profitable quarters Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, continues its steady growth trajectory by leveraging several emerging technology trends. In particular, the company is leveraging its go-to Loyalty platform that incorporates a Gamification component. Gamification adds an extra…

TuesdayJul 12, 2022 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Enhances Bioavailability of Orally Administered APIs

Lexaria is a global innovator in drug delivery platformsThe company has developed the patented DehydraTECH(TM) technology that significantly improves the bioavailability of orally administered pharmaceuticals and therapeuticsBioavailability is the fraction of a drug that reaches the site of action or systemic circulationWhile drugs delivered intravenously are 100% bioavailable, drugs that have any other route of administration, such as oral, have reduced bioavailabilityDehydraTECH enhances the bioavailability of APIs, in part, by bypassing first-pass liver processing Global innovator Lexaria Bioscience (NASDAQ: LEXX) has built a reputation as a developer of drug delivery platforms, the most notable of which is the patented DehydraTECH(TM)…

MondayJul 11, 2022 11:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment

Novel brain cancer drug developer CNS Pharmaceuticals, Inc. has received approval from the U.S. FDA for a Protocol Amendment that expands patient eligibility for participation in its potentially pivotal Phase 2 clinical trial for a novel drug candidate that targets the nearly 100 percent fatal cancer glioblastoma (“GBM”)CNS is developing the drug candidate Berubicin as an alternative to the standard-of-care chemotherapy agent, Lomustine, with the hope that Berubicin will prove itself at least as effective and potentially more so Berubicin has demonstrated the capacity to cross the blood-brain barrier in order to attack central nervous system tumors directly, which grants it…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Category: Tiny Gem